AIMS: Veins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. METHODS AND RESULTS: The inferior vena cava was excised from donor rats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100% CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 3-6 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. CONCLUSION: Ex vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.
AIMS: Veins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. METHODS AND RESULTS: The inferior vena cava was excised from donorrats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100% CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 3-6 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. CONCLUSION: Ex vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.
Authors: H Morisaki; T Katayama; Y Kotake; M Ito; T Tamatani; S Sakamoto; Y Ishimura; J Takeda; M Suematsu Journal: Anesthesiology Date: 2001-07 Impact factor: 7.892
Authors: T Zubilewicz; J Wronski; A Bourriez; P Terlecki; A M Guinault; B Muscatelli-Groux; J Michalak; D Méllière; J P Becquemin; E Allaire Journal: Med Sci Monit Date: 2001 Mar-Apr
Authors: Leo E Otterbein; Brian S Zuckerbraun; Manabu Haga; Fang Liu; Ruiping Song; Anny Usheva; Christina Stachulak; Natalya Bodyak; R Neal Smith; Eva Csizmadia; Shivraj Tyagi; Yorihiro Akamatsu; Richard J Flavell; Timothy R Billiar; Edith Tzeng; Fritz H Bach; Augustine M K Choi; Miguel P Soares Journal: Nat Med Date: 2003-01-21 Impact factor: 53.440
Authors: Marlies E J Reinders; Masayuki Sho; Atsushi Izawa; Ping Wang; Debabrata Mukhopadhyay; Kerith E Koss; Christopher S Geehan; Andrew D Luster; Mohamed H Sayegh; David M Briscoe Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Atsunori Nakao; Kei Kimizuka; Donna B Stolz; Joao Seda Neto; Takashi Kaizu; Augustine M K Choi; Takashi Uchiyama; Brian S Zuckerbraun; Michael A Nalesnik; Leo E Otterbein; Noriko Murase Journal: Am J Pathol Date: 2003-10 Impact factor: 4.307
Authors: Qiang Sun; Tomohiro Kawamura; Kosuke Masutani; Ximei Peng; Qing Sun; Donna B Stolz; John P Pribis; Timothy R Billiar; Xuejun Sun; Christian A Bermudez; Yoshiya Toyoda; Atsunori Nakao Journal: Cardiovasc Res Date: 2012-01-27 Impact factor: 10.787